From theoretical synergy to clinical supra-additive toxicity
- PMID: 19224836
- DOI: 10.1200/JCO.2008.20.8595
From theoretical synergy to clinical supra-additive toxicity
Comment on
-
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.J Clin Oncol. 2009 Mar 20;27(9):1432-9. doi: 10.1200/JCO.2008.19.0108. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224847 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
